What type of study is this?

This is a Cohort Study study (also classified as: Human Clinical Trial).

What question did this study set out to answer?

To identify risk factors associated with failure to complete step-up dosing of bispecific antibody therapy in B-cell lymphomas.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

To identify risk factors associated with failure to complete step-up dosing of bispecific antibody therapy in B-cell lymphomas.
Conducted a retrospective analysis at a single center.
Included patients with histologically confirmed relapsed/refractory large B-cell lymphoma or follicular lymphoma.
Analyzed demographic and clinical characteristics of patients who received bispecific antibodies.
14 out of 109 patients did not complete step-up dosing.
Elevated LDH and diagnosis of large B-cell lymphomas were significant predictors of failure to complete dosing.
Cap rates for complete response and progression-free survival indicate potential treatment challenges.

No takes yet. Share an insight, caveat, or question.

Retrospective analysis revealed risk factors affecting completion of dosing in B-cell lymphomas, suggesting potential improved strategies.

Jordan S. Carter (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Retrospective analysis revealed risk factors affecting completion of dosing in B-cell lymphomas, suggesting potential improved strategies.